<DOC>
	<DOCNO>NCT00960167</DOCNO>
	<brief_summary>Hepatocellular carcinoma ( HCC ) one lead malignancy Taiwan . Surgery local ablative therapy remain treatment choice curative purpose . Transarterial chemoembolization mainstay intrahepatic control patient candidate local modality treatment . Sorafenib recently integrate treatment option , mainly intrahepatic extrahepatic wide spread disease contraindicate modality . External radiotherapy ( RT ) selectively used patient localize hepatic tumor ( ) refractory treatment option . The data retrospective study bias patient selection uncontrolled comparison patient receive RT . The obstacle RT HCC remain unanswered heterogeneity dose radiation low tolerance liver RT viral hepatitis carrier . Such sublethal dose might associate unsatisfactory tumor control , intra-/extra-hepatic metastasis , radiation-induced liver disease significant proportion HCC patient . The purpose phase I study primarily determine maximally tolerate dose RT , secondarily evaluate tumor control , ass pattern failure survival , analyze characteristic radiation-induced liver disease , well collect blood sample translational research . HCC patient hepatitis B virus carrier grade Child-Pugh A cirrhosis enrol . This dose escalation trial conduct 7-Gy increase 2 fraction ( 3.5 Gy per fraction ) total four level , 42 Gy 63 Gy . Conformal RT three-dimensional design , intensity modulate RT , volumetric modulate arc therapy use define dose-volume threshold normal liver structure . Five patient treat dose level , dose limit toxicity le 2 patient judge acceptable . A minimum 15 patient require start dose level 49 Gy treat tumor diameter le 10 cm . Imaging modality use estimate treatment response detect metastasis . Serum analyse do evaluate hepatic function , viral load , hematological toxicity , translational research angiogenic inflammatory study .</brief_summary>
	<brief_title>A Dose Escalation Trial Radiation Therapy ( RT ) Hepatocellular Carcinoma ( HCC )</brief_title>
	<detailed_description>Synopsis All enrol patient receive 3.5 Gy per fraction ( five fraction per week ) following level ; Dose escalation 7 Gy 2 fraction maximum 63 Gy , follow : Dose Level I : 3.5 Gy 12 fraction ( 42 Gy total ) Dose Level II* : 3.5 Gy 14 fraction ( 49 Gy total ) Dose Level III : 3.5 Gy 16 fraction ( 56 Gy total ) Dose Level VI : 3.5 Gy 18 fraction ( 63 Gy total ) *Protocol treatment begin level 2 patient sum diameter irradiate tumor ( ) less 10 cm . Patient population : Hepatocellular carcinoma base diagnostic criterion European Association Study Liver ( EASL ) , either confirm cyto-histologically confirm non-invasively ( restrict cirrhotic patient ) radiological criterion ( two coincident image technique focal lesion &gt; 2 cm arterial hypervascularization ) combine criterion ( one imaging technique associate alpha-fetoprotein ( AFP ) , focal lesion &gt; 2 cm arterial hypervascularization , AFP level &gt; 400 ng/ml ) ; Hepatitis B virus carrier serologically ; Child-Pugh grade A cirrhosis ; The patient consider suitable surgery , ablation therapy , trans-arterial chemoembolization judge care physician . In addition , systemic anti-cancer therapy high priority available judge care physician . Required sample size : Minimum 15 ( start level II ) OBJECTS Primary To identify maximally tolerate dose ( 42 Gy 63 Gy 3.5 Gy per fraction ) , conformal radiation therapy patient HBV-related Child-Pugh grade A cirrhosis hepatocellular carcinoma ( HCC ) eligible conventional treatment modality . Secondary To evaluate local tumor control rate within irradiate field . To assess patterns failure survival patient treat conformal liver radiation therapy . To analyze dose volume characteristic influence whether radiation-induced liver disease ( RILD ) , HBV reactivation , toxicity occur . To collect blood sample translational research . RADIATION THERAPY : Radiation therapy must start within 4 week patient registration . Intensity modulate radiation therapy volumetric modulate arc therapy acceptable . Helical tomotherapy cyberknife allow study . H2 blocker proton pump inhibitor require attempt reduce risk late gastrointestinal bleeding . Oral anti-viral agent allow discretion treat physician prevent reactivation HBV . Dose specification The target dose determine base study dose level volume normal liver exclude radiation , use liver dose-volume histogram ( DVH ) . Treatment allocate dose level permit normal tissue criterion maintain . If normal tissue criterion meet dose , treatment low dose level permit , long normal tissue constraint meet low dose level . The dose per fraction planning target volume ( PTV ) 3.5 Gy . Dose start dose level 2 ( 49 Gy ) , may vary 42 Gy 63 Gy , 12 18 fraction , Monday Friday , 2-fraction increment . The start level Level 2 , 49 Gy 14 fraction patient sum diameter irradiate tumor ( ) less 10 cm Child-Pugh grade A liver cirrhosis , level 1 , 42 Gy 12 fraction patient otherwise . Doses prescribed peripheral cover isodose cover PTV . Assuming dose normalize isodose 100 % , maximal dose 120 % minimum PTV dose 90 % . Any dose &gt; 110 % must within PTV ( except adjacent tumor , maximum dose outside PTV must &lt; 115 % ) . Minor variation define minimum PTV dose fall 85 90 % ( require 100 % isodose prescription ) . Major variation ( unacceptable ) define minimum PTV dose &lt; 85 % ( require 100 % isodose prescription ) . The acceptable exception underdose PTV adjacent small bowel keep less 3cc small bowel stomach dose 42 Gy . This part PTV specify record . Maximum dos define 1 cc volume . Minimum dose PTV define minimum dose 99.0 % PTV . *Protocol treatment begin level 2 patient sum diameter irradiate tumor ( ) less 10 cm Child-Pugh grade A liver cirrhosis . The minimum , maximum , mean dose PTV record gross tumor volume ( GTV ) . Technical factor External beam equipment : Treatment deliver 6 - 25 MV photon , selection appropriate energy optimize radiotherapy dose distribution within target volume minimize dose non-target tissue . Localization , simulation immobilization Patient positioning base clinical judgment best achieve ideal dose distribution . The target volume identify IV contrast CT scan and/or MRI register plan CT dataset . The planning CT subsequent CT study obtain use identical immobilization technique use treatment . An immobilization frame may use , require . A variety immobilization method may utilize planning treatment , include active breathing control ( ABC ) , voluntary breath hold , gate , shallow breathing , abdominal compression . For free breathing , 4D-CT use aid PTV definition . Treatment planning/volume definition CT-based 3D treatment plan shall use patient . Intensity modulate radiation therapy ( IMRT ) use select patient breathe control device IMRT . The GTV define IV contrast CT MRI . The clinical target volume ( CTV ) GTV + 5 mm , within liver . The PTV determine immobilization device use and/or individual patient breathe motion . The minimal maximal PTV margin permit 4 mm 30 mm , respectively , dependent immobilization method use breathe motion . DVH shall calculate liver ( liver minus GTVs ) , kidney , spinal cord , small bowel stomach well target lesion ( GTVs . CTVs , PTVs ) . The maximum , minimum , mean dose dose per fraction must document . Critical structure Normal liver : The normal liver define normal liver volume minus GTV . In patient , require least 700 cc normal liver . No 30 % normal liver may receive 27 Gy , 50 % normal liver may receive 24 Gy . Kidney : No 50 % combined renal volume may receive 20 Gy . Spinal cord : Maximal permit dose spinal cord 37 Gy . Small bowel : Maximal permit dose small bowel 42 Gy 3 cc volume . The underdose PTV adjacent small bowel stomach acceptable . Stomach : Maximal permit dose stomach 42 Gy 3 cc volume . All dose physical dos ( biologically correct ) . Note 42 Gy biologically equivalent 56.8 Gy 2 Gy/fraction use α/β 3 . Radiation adverse event Liver : Radiation therapy hold point protocol CTCAE v3.0 hepatic adverse event Grade 4 . It expect proportion patient transient elevation liver enzymes follow treatment ( possibly Grade 3 CTCAE level ) . If elevation liver enzymes observe Grade 3 level , frequent measurement ( least week ) liver enzymes recommend enzyme stabilize return baseline level . Repeat Grade 4 blood work require least 5 day follow first abnormal lab value determine Grade 4 level transient ( define &lt; 5 day ) persistent . Patients evaluate 1-month 3-month follow-up visit symptom sign radiation induce liver disease ( RILD ) . In patient elevation liver enzymes near Grade 4 level and/or patient early non-specific sign symptom liver injury , close follow-up recommend repeat blood work . If tumor progression document patient , liver injury presume treatment relate . HBV-related hepatitis : HBV-related hepatitis flare define great 3-fold increase pre-treatment baseline serum ALT level 100 IU/L . The HBV-related hepatitis flare ( HBV reactivation ) accompany precede simultaneous great 10-fold increase , compare previous nadir level , HBV DNA reappearance hepatitis B e antigen ( HBeAg ) serum patient whose baseline HBeAg negative . Oral anti-viral agent initiate patient without prophylactic use oral antiviral agent HBV reactivation confirm . Gastrointestinal : The dose constraint require normal stomach small intestine limit GI toxicity observe expected GI toxicity dose limit . However , portion stomach small intestine treat ( &gt; 30 Gy ) , H2 blockers proton pump inhibitor require attempt decrease chance late GI bleeding . Patients follow GI toxicity follow visit . Other : The occurrence Grade 4 adverse event , relate protocol treatment , organ system prompt discontinuance protocol therapy appropriate physical examination , laboratory , image assessment undertaken . Protocol treatment resume absence recovery adverse event magnitude . Once recovery grade 1 occur , treatment may continue discretion treat physician . Evaluation partial complete response base 3-month follow-up CT scan . Only gross increase tumor size see less time score progressive disease . Response radiation may continue 12 month follow-up time maximal response record . Measurement Response Response evaluate study use international criterion propose Response Evaluation Criteria Solid Tumors ( RECIST ) Committee . The sum long diameter ( LD ) target lesion calculate reported baseline sum LD . The baseline sum LD use reference characterize objective tumor . Response Criteria : Evaluation target lesion Complete Response ( CR ) : Disappearance target lesion . Any pathological lymph node ( whether target non-target ) must reduction short axis &lt; 10 mm . Partial Response ( PR ) : At least 30 % decrease sum diameter target lesion , take reference baseline sum diameter . Progressive Disease ( PD ) : At least 20 % increase sum diameter target lesion , take reference small sum study ( include baseline sum small study ) . In addition relative increase 20 % , sum must also demonstrate absolute increase least 5 mm . ( Note : appearance one new lesion also consider progression ) . Stable Disease ( SD ) : Neither sufficient shrinkage qualify PR sufficient increase qualify PD , take reference small sum diameter study In-field local control : For study , local control define lack progressive disease treat field . Cause death : The treat physician evaluate whether cause death hepatic non-hepatic , and/or due tumor due toxicity SPECIMEN COLLECTION FOR TRANSLATIONAL RESEARCH Peripheral Blood Collection Sample collection time point : Blood sample collect 5 occasion along protocol treatment : 1. baseline ( within 1 week first radiotherapy fraction ) ; 2 . 5-10 day last radiotherapy fraction ; 3 . 4 week last radiotherapy fraction . Preparation Plasma Buffy coat : 1 . Collect 5-10 mL anticoagulated blood ( EDTA ) . Invert tube several time assure blood mixed thoroughly anticoagulant . 2 . Using three ( 3 ) 1mL cryovials , label patient 's case number , procedure date , clearly mark cryovials `` plasma '' . Similarly , label three ( 3 ) 1mL cryovials mark `` buffy coat '' . Process : 1 . Centrifuge specimen within one hour collection . EDTA ( purple top ) tube centrifuged standard clinical centrifuge ~2500 RPM 4° Celsius 10 minute . 2 . If interval specimen collection processing anticipate great one hour , keep specimen ice centrifuge do . 3 . Remove plasma close buffy coat take cared disturb white cell layer . Aliquot plasma three 1mL cryovials label RTOG study case number , procedure date , clearly mark `` plasma '' . 4 . Remove buffy coat cell carefully place 1 mL cryovials label `` buffy coat '' ( okay pack red cell buffy coat layer inadvertently collect process ) 5 . Place cryovials biohazard bag . 6 . Store plasma buffy coat specimens frozen . Buffy coat sample must ship tissue bank within one ( 1 ) week collection . Preparation Serum : 1 . Collect one 5-10 mL red-topped tube . Allow 30 minute clot room temperature processing . 2 . Using four ( 4 ) 1ml cryovials , label study number , patient 's case number , procedure date , clearly mark cryovials `` serum '' . Process : 1 . Allow one 5ml red top tube clot 30 minute room temperature . 2 . Spin red-topped tube standard clinical centrifuge ~2500 RPM 4°Celsius 10 minute . 3 . Aliquot serum four 1mL cryovials label RTOG study case number , procedure date , mark `` serum '' . 4 . Store serum frozen ( -80° Celsius ) ready ship Analysis Blood Samples Serum plasma sample : Soluble cytokine growth factor relate inflammation angiogenesis analyze enzyme-linked immunosorbent assay ( ELISA ) serum sample plasma sample . Inflammatory factor , IL-6 , TNF-alpha , CRP , MMP-2 , MMP-9 , VEGF , IL-8 , pro-angiogenic factor , VEGF , basic-FGF , PDGF , PIGF , TNF , anti-angiogenic factor , thrombospontin-1 ( TSP-1 ) , include . Serum HBV DNA level also analyze . RNA sample blood mononuclear cell : 1 . Tumor-associated gene expression peripheral blood reflect presence circulate hepatocellular carcinoma ( HCC ) cell might associate aggressive feature HCC . We assess prognostic significance AFP human telomerase reverse transcriptase protein ( hTERT ) mRNA expression peripheral blood HCC patient . 2 . Circulating endothelial cell progenitor show surrogate marker angiogenic activity . Several cellular marker , include VEGFR2 , Tie-2 , CD133 , show specifically express activate endothelial cell endothelial progenitor cell . The expression marker detect real-time quantitative PCR . DNA sample blood mononuclear cell : The polymorphic inheritance human drug-metabolizing enzyme , encode glutathione-S-transferase ( GST ) , microsomal epoxide hydrolase ( mEPHX ) , CYP system , implicated cancer risk prognosis . DNA sample blood mononuclear cell use analysis GST , mEPHX , CYP , p53 polymorphism PCR sequence analysis . Data Management Analysis 1 . Evaluation soluble factor related inflammation angiogenesis surrogate quantification circulate endothelial cell progenitor ( B-2 section ) conduct accord standard procedure personnel access clinical outcome patient . 2 . The clinical outcome patient include correlation study include clinical response ( responder vs. non-responders ) , pattern failure ( intrahepatic recurrence outside radiation field vs. intrahepatic recurrence ; extrahepatic metastasis vs. metastasis ) , radiation induce liver disease ( RILD vs. RILD ) , survival . 3 . The correlation clinical outcome surrogate marker evaluate after-mentioned marker make . STATISTICAL CONSIDERATIONS Study Endpoints The primary endpoint study determine maximally tolerate dose highly conformal radiation therapy patient HCC . The secondary endpoint evaluate local control rate within irradiate field , ass pattern failure survival , analyze dose volume characteristic influence whether RILD , HBV reactivation , toxicity occur . Sample Size Evaluation Adverse Events Adverse event grade accord CTCAE v. 3.0 criterion . Dose limit toxicity ( DLT ) define follow occur within 90 day start treatment : ) grade 4 5 hepatic b ) grade 4 5 gastrointestinal c ) grade 4 5 thrombocytopenia ) Radiation Induced Liver Disease ( RILD ) require treatment ( include diuretic ) . RILD define use follow adverse event : ) grade 3 high alkaline phosphatase ( ALP ) presence ascites occur absence disease progression ii ) grade 4 hepatic liver enzyme elevation persist ≥ 5 day e ) adverse event require interruption therapy ≥ 2 week ( 14 calendar day ) . This include patient desire discontinue therapy . It include failure thrombocytopenia improve level 80 require interruption therapy . f ) Any grade 5 adverse event The goal study determine maximally tolerate dose ( MTD ) patient HCC , rate DLT le 35 % . Dose Escalation The follow four possible dose level study : Dose Level I : 3.5 Gy 12 fraction ( 42 Gy total ) Dose Level II : 3.5 Gy 14 fraction ( 49 Gy total ) Dose Level III : 3.5 Gy 16 fraction ( 56 Gy total ) Dose Level VI : 3.5 Gy 18 fraction ( 63 Gy total ) Patients receive highly conformal radiotherapy start Dose Level II . Dose level escalate 7 Gy 2 fraction per level 21 Gy 6 fraction total dose 63 Gy . Evaluable patient define eligible patient begin treatment . After 5 evaluable patient follow minimum 90 day start treatment , 0 1 DLT , dose level judge acceptable . If occurs , patient begin accrue next high dose level . If ≥ 3 5 patient DLT , precede dose level declare MTD . If 2 5 patient DLT , addition 5 patient level do . If ≥ 4 10 patient DLT , precede dose level declare MTD . If 2 3 10 patient DLT , patient begin accrue next high dose level . If 3 DLT start dose level ( Dose Level II ) , dose de-escalated Dose Level I . If occurs , 5 evaluable patient follow minimum 90 day start treatment Dose Level I , 0 1 DLT , 3.5 Gy per fraction total 42 Gy declare MTD . If time grade 5 treatment-related adverse event observe , study chair review event . The number evaluable patient need depend number time dose escalate possibly de-escalated . If escalation continue Dose Level IV , 15 evaluable patient require . If dose de-escalated Dose Level II , 10 evaluable patient require .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Eligible patient include HCC base diagnostic criterion European Association Study Liver ( EASL ) , either confirm cytohistologically confirm noninvasively ( restrict cirrhotic patient ) radiological criterion ( two coincident image technique focal lesion &gt; 2 cm arterial hypervascularization ) combine criterion ( one imaging technique associate AFP , focal lesion &gt; 2 cm arterial hypervascularization , AFP level &gt; 400 ng/ml ) . They ChildPugh grade A cirrhosis HBsAgpositive 6 month . These patient feasible conventional treatment modality treatment include surgery , transarterial embolization , ethanol injection , radiofrequency ablation . No systemic anticancer therapy high priority available . All 3 criterion judge care physician . All intrahepatic disease must encompass within radiation field , except intrahepatic disease outside radiation field ( ) control treatment modality radiotherapy . Karnofsky Performance Scale ≧ 80 . Age &gt; 18 . Adequate bone marrow function , define follow : Absolute neutrophil count ( ANC ) &gt; 1,000 cells/mm3 base upon CBC/differential obtain within 2 week prior registration study Platelets &gt; 20,000 cells/mm3 base upon CBC/differential obtain within 2 week prior registration study Hemoglobin &gt; 8.0 g/dl base upon CBC/differential obtain within 2 week prior registration study ( Note : The use blood transfusion intervention achieve Hgb &gt; 8.0 g/dl acceptable . ) Previous liver resection , embolization , ablative therapy permit . Chemotherapy and/or target agent therapy must complete least 2 week prior radiation . Women childbearing potential male participant must practice adequate contraception . Patient must sign informed consent prior study entry . Pretreatment evaluation eligibility include : A complete history general physical examination For woman childbearing potential , serum urine pregnancy test must perform within 72 hour prior registration INR , total bilirubin , albumin , alkaline phosphatase , AST , ALT within 1 week prior study entry At least 1 unidimensionally measurable lesion ≥ 20 mm conventional technique OR least 10 mm spiral CT scan Prior invasive malignancy , HCC , ( except nonmelanomatous skin cancer ) unless disease free minimum 3 year ( For example , carcinoma situ breast , oral cavity , cervix permissible ) . Prior radiotherapy region study cancer would result overlap radiation therapy field . Tumor thrombosis main trunk portal vein , hepatic vein , inferior vena cava . ChildPugh grade B C cirrhosis . Extrahepatic metastasis . Clinical ascites require diuretic treatment paracentesis symptom relief . Serum alanine aminotransferase ( ALT ) level &gt; 5X normal upper limit total bilirubin level &gt; 3.0 . Active hepatitis ( serum ALT level &gt; 5X normal upper limit ) clinically significant liver failure . Positivity antiHCV , pregnancy , nurse woman , woman childbearing potential , men sexually active willing/able use medically acceptable form contraception ; exclusion necessary treatment involve study may significantly teratogenic .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>HCC</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>dose escalation</keyword>
	<keyword>Toxicity</keyword>
	<keyword>Local control</keyword>
</DOC>